Tecentriq and Avastin revenue trends

In 1Q17, 2Q17, and 3Q17, Roche’s (RHHBY) Avastin generated revenues of 1.7 billion Swiss francs, 1.7 billion Swiss francs, and 1.6 billion Swiss francs, respectively. In 1Q17, 2Q17, and 3Q17, Tecentriq generated revenues of 115 million Swiss francs, 121 million Swiss francs, and 128 million Swiss francs, respectively.

What to Expect from Roche’s Tecentriq and Avastin in 2018

IMmotion 151 trial

In December 2018, Roche announced results from the phase three IMmotion 151 trial. In the IMmotion 151 trial, Tecentriq and Avastin combination therapy met the co-primary endpoint of progression-free survival compared to sunitinib.

Roche conducted the phase three IMmotion 151 trial to evaluate the safety and efficacy of Tecentriq and Avastin combination therapy compared to sunitinib for the treatment of individuals with locally advanced or metastatic renal cell carcinoma who have not previously received systemic therapy.

In the IMmotion 151 trial, Tecentriq and Avastin demonstrated a statistically significant and clinically meaningful decrease in the risk of disease worsening or death (progression-free survival) in individuals with advanced or metastatic renal cell carcinoma whose tumors expressed PD-L1 (programmed death-ligand 1) protein compared to sunitinib as a first-line treatment.

The results of the clinical trial will be discussed with health authorities including the European Medicines Agency and the US Food and Drug Administration (or FDA).

About Tecentriq and Avastin

Tecentriq is indicated for the treatment of individuals with locally advanced or metastatic urothelial carcinoma who are not candidates for cisplatin-containing chemotherapy or showed disease progression during or after any platinum-containing chemotherapy. Tecentriq is also indicated for the treatment of individuals with metastatic non-small cell lung cancer who showed disease progression during or after platinum-containing chemotherapy. Avastin is indicated for metastatic colorectal cancer.

Tecentriq’s peers include Pfizer’s (PFE) Bavencio, Bristol-Myers Squibb’s (BMY) Opdivo, and Merck’s (MRK) Keytruda. The revenue growth of Roche’s Avastin and Tecentriq could boost the Vanguard FTSE All-World ex-US ETF (VEU). Roche makes up about ~0.69% of VEU’s total portfolio holdings.

Latest articles

On June 25, AbbVie (ABBV) announced that it plans to buy Allergan (AGN) for ~$63 billion. At 10:20 AM ET, Allergan stock rose 27%, while AbbVie stock fell 15%.

On June 25, Credit Suisse initiated its coverage on Shake Shack with an “outperform” rating and a target price of $77—an upside potential of 15.4% from its closing price of $66.72 on June 24.

On June 25, the soft economic data isn't an isolated case. We have been getting a flurry of dismal data points. The US economy added only 75,000 non-farm jobs in May.

French retail giant Carrefour has agreed to sell an 80% stake in its China operations for ~$705 million to Suning.com, an Alibaba (BABA) backed company. While China represents a massive opportunity with its almost 1.4 billion population, it has not been an easy market for foreign companies, at least when it comes to retail and e-commerce.

On June 25, US Secretary of Agriculture Sonny Perdue told CNN in an interview that the US-China trade war has impacted US farmers. He said that farmers “are one of the casualties” of the trade war.

25 Jun

Hang Seng and Nikkei 225 Lose amid Trade Worries

WRITTEN BY Mayur Sontakke, CFA, FRM

After rising marginally yesterday, Hong Kong’s Hang Seng Index fell today. The index lost 1.15% to end at 28,185.98. Only seven stocks in the index rose, while 39 declined. Four remained unchanged. Tencent Holdings (TCEHY) was one of the worst performers with a 1.8% fall.